PetLife Pharmaceuticals Inc - PowerPoint PPT Presentation

Loading...

PPT – PetLife Pharmaceuticals Inc PowerPoint presentation | free to download - id: 83131f-ZWZiM



Loading


The Adobe Flash plugin is needed to view this content

Get the plugin now

View by Category
About This Presentation
Title:

PetLife Pharmaceuticals Inc

Description:

PetLife Pharmaceuticals, Inc. (PetLife Pharma) has developed and is launching a new generation of potentiated veterinary cancer medications and nutraceuticals. – PowerPoint PPT presentation

Number of Views:32
Slides: 29
Provided by: petlifepharma
Category: Pets & Animals

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: PetLife Pharmaceuticals Inc


1
(No Transcript)
2
Escozine for Pets
TM
New frontier in pet oncological treatment based
on blue scorpion venom, which has been used for
years to to treat humans with cancer in many
countries
Revolutionary new drug, with proven ability to
reduce tumor size- no signs of toxicity or
complications observed during clinical use.
Can be easily administered, has healthy profit
margins, market acceptance will be quick,
translating to high sales growth
3
The Problem
Pets are living longer than ever before, making
them more susceptible to developing cancer
  • Cancer is the 1 disease related cause of death
    for dogs in the U.S.
  • Cancer accounts for almost 50 of deaths in pets
    older than 10 years
  • Average costs to treat lymphoma in pets is
    2,000-most owners will rather watch their pets
    die than pursue treatment
  • 1 in 4 dogs and 1 in 5 cats will develop cancer
    in their lifetime
  • Dogs get cancer at about the same rate as humans

4
Current Solutions
The most common treatment modalities used to
combat cancer include Surgical treatment,
Chemotherapy, Radiation Therapy and Immunotherapy.
PALLADIA is the first and only FDA-approved drug
for canine cancer. While it is administered
orally, it is still technically chemotherapy.
Side effects may include low white blood cell
counts, diarrhea, vomiting, lethargy, fatigue,
and stomach ulceration. Low response rate,
roughly 40 of dog with mast cell tumors will
actually respond to the drug, while the majority
do not.
(US National Library of Medicine National
Institutes of Health)
5
(No Transcript)
6
Market Opportunity
Breakdown Spending on Pets in 2015 ( billions)
  • In 2015, 60.28 billion was spent on pets in the
    U.S.-26 on vet care services

Food
23.05
Supplies/OTC Medicine 14.28
Vet Care
15.42
Live animal purchases
2.12
Pet Services grooming boarding 5.41
7
Market Opportunity
Current treatment methods are quite expensive and
not totally safe for pets
Initial visit, including diagnosis, discussion of
prognosis and a treatment plan
200
Major surgery to remove a tumour deep in the
body, or that requires reconstruction
1500
Chemotherapy (depends on the size of the dog)
ranges from 200 to 2,000 and up
Radiation therapy
ranges from 2,000 to 6,000
Pain medications
25 to 50 a month.
8
CASE REPORT
Prohibitive treatment costs means some owners
have no choice but to let their pets die rather
than seeking further treatment
I Amount spent 3,000 Posted by Irena in
Vancouver. CA, Breed Shepxgolden Treatment
Owner Took no action/did not
seek further treatment
Posted March 3rd, 2011 0803 PM Cancer
Type Intestinal
My beautiful 12 years boy started vomiting and
lost 20 lb. Bl.test 2x, great, extray stomach ,
lungs great. Everything was great, but Sky was
starved to death in front my eyes. 2 months
nightmare, cry from pain, cannot eat, horrible.
Ultrasound mass tumor. Surgery, just open his
belly told me cancer is in lymp.nodes, have one
months to live if most. My boy suffered so much,
so much , I let him go, when sleep on oper,
table, hug him and let him go. I cant let him
suffer more. Was very, just like that, on and off
2 months.
9
Introducing a new generation of HP
(high potency) veterinary cancer medications and
nutraceuticals
NEYMAR BLACK
Entertainment
Escozine for Pets Immunity Booster
Escozine for Pets
Escozine for Pets Supplements and
Nutraceuiticals
10
Escozine for Pets
  • Escozine for Pets is a an innovative
    polarized, potentiated bio-active peptide
    extracted from the Blue Scorpion (Rhopularus
    Princeps)
  • Induces apoptosis on a variety of cancer cells by
    a pattern of DNA fragmentation
  • It is based on the same-patented formula of
    Escozine used for the treatment of cancer in
    humans but is amplified through polarization
    technology

11
ESCOZINE FOR PETSTM inhibits blood vessel growth
(angiogenesis) in solid tumors. Chlorotoxin
blocks trans-membrane fluxes of chlorine and
regulates the adjusting of cell growth, cell
division and metastasis thereby inducing tumor
cell death (apoptosis). The regulating of
activity of the potassium (K) 3-4 kDa, sodium
(N) 6-8 kDa and chloride (CL) voltgate ionic
channels of the tumor cells leads to growth
arrest and causes cell death (apoptosis)
additionally, calcium dependent potassium
channels inhibit growth of other cancer
cells. Innovation Therapeutics (2015). Review of
Pre-clinical Clinical data and Scorpion Venom
studies to further support clinical research
development and registration of EscozineTM for
Pet Life.
12
Escozine for Pets
Escozine for Pets has a number of advantages
over current treatment regimens
  • It can be used along with the traditional forms
    of cancer treatment
  • Sensitizes cancer cell resistance, thereby
    increasing the efficacy of other drugs used in
    treating the cancer in the animal.
  • Has selective binding preferences with malignant
    cells .
  • Easy administering orally
  • Cost effective

13
Escozine - A Breakthrough in Cancer
Treatment and Prevention
Documented clinical observations
  • Reduction in pain
  • Enhancement of the recipients immune-system
  • Reduction of cancerous cell multiplication
  • Inhibition of new blood vessel formation from
    pre-existing cancerous cells.
  • Improvement in quality of sleep
  • Reduction of inflammation
  • Dramatic reduction in the painful side-effects of
    chemotherapy and radiation treatment
  • Improvement of appetite

14
Testimonials
It has now been almost 1 year and 5 months since
Bootsie's lung tumor diagnosis and 1 year and 3
months of being on Escozine. I can't thank the
PetLife team and our vet, Dr Mitchell, for making
this and introducing it to us. I never imagined
she would still be with us today. If you saw and
interacted with Bootsie, you wouldn't even know
she had a tumor. She is an up beat 16 year old
cat (if there is such a thing) who still loves
sitting by the window sun bathing and watching
the birds, playing and grooming her sisters (2
younger cats), and snuggling with my husband and
me.
When we started Bootsie on the Escozine, we were
only hoping for it to help her lung tumor,
however, we think it may be helping other health
conditions she has. For the last 5 or so years
now, Bootsie has had kidney disease as well. Just
2 months ago (Oct 2015) when our doctor did a
routine blood panel check and urine check for her
kidneys, her results look the best they've been
in a few years! We are amazed at what this is
doing for our baby's health. For a then 15 year
old cat who was given only 3 months to live now
being 16 years old and making it 1 year and 5
months past diagnosis is a true miracle for us.
Thanks again, Escozine!
anonymous
anonymous
15
Testimonials
My 9-year-old toy poodle, Ophelia, developed
multiple breast lumps. She's been under the care
of Dr. Joel Beth Mitchell of Aventura Animal
Hospital and Resort. Dr. Mitchell had to perform
several extensive surgeries in order to remove
them all. Some biopsy results came back as
low-grade carcinomas. We were devastated. Those
were very dark times. Dr. Mitchell, whose opinion
we hold in the highest regard, told us about
Escozine. Some of her cancer patients who had had
grim prognoses in the past, are alive and well,
and they are taking Escozine. I was intrigued and
encouraged, started reading a lot of literature
on blue scorpion venom and decided to try it. I'm
so glad I did. Ophelia has recovered remarkably
well after very difficult surgeries. She's happy,
full of energy and does not show any signs of
sickness anymore, thank G-d. Escozine is very
easy to administer. I only wish I could teach
Ophelia to take it herself??. Very grateful to
Dr. Mitchell and Escozine team. Please continue
your research and development. It benefits
animals and people as well. Thank you!
anonymous
16
Revenue Model
Step 1. It is important that we first generate
interest in Escozine for PetsTM. We will generate
buzz through online articles, social media
posts, videos, and during animal events Step 2.
An animal specialist analyzes the needs of the
animal and prescribes Escozine for Pets alone or
in combination with other treament Step 3
Management of pet condition. The pet is monitored
to ensure it is responding to treatment. Step 4
Encourage owners whose pets have been cured to
spread word about Escozine
anonymous
17
Revenue Growth to be Driven
by New Customer Acquisitions
  • Expanding into new geographical markets. Each
    year, the company will open a new distribution
    center in a strategic geographical market i.e.
    India, Latin America and others
  • Ease of availability, cost effectiveness, easy
    administering, and aggressive brand building
    activities, will drive sales increases at a fast
    pace, year on year

18
Competition
Description
Competitor
Company/Drug
Conditionally approved by FDA in 2010,
Kinavet-CA1, is a tyrosine kinase inhibitor. It
is used to treat mast cell tumors, a common form
of cancer that affects dogs. Kinavet-CA1 works
in three ways by blocking the survival signal of
the tumor cells, which may induce disappearance
of the tumor, by preventing tumor growth and
preventing the spread of tumor cells (metastasis).
Paccal Vet-CA1 has been granted conditional
approval by the FDA for the treatment of
non-resectable stage III, IV or V mammary
carcinoma in dogs that have not received previous
chemotherapy, or radiotherapy and resectable and
non-resectable squamous cell carcinoma in dogs
that have not received previous chemotherapy, or
radiotherapy.
The only drug fully approved by the FDA for the
treatment of cancer in canines is Palladia.
Palladia is a prescription-only therapy is used
to treat grade II or III recurrent cutaneous mast
cell tumors with or without regional lymph node
involvement. It works by blocking the activity of
key receptors important in the development of
blood vessels that supply tumors, as well as
receptors vital for tumor survival.
19
Competitive Advantage
Esozine for Pets will succeed against
competition in a number of areas
  • Toxic cancer treatments for pets creates pent up
    demand for PetLifes non-invasive products.
  • Patent Protection PetLife has an exclusive
    license and rights to the patent on Polarized
    Scorpion Venom
  • Projected rapid sales growth and high gross
    margins gives room to adjust pricing for
    competitiveness
  • Complementary treatment properties Escozine for
    PetsTM can be used as complementary treatment to
    chemotherapy drugs

20
Positioning
We will position Escozine for Pets in the market
as a non-invasive, cost effective (249 cost of
treatment per patient for each month) drug in the
pet oncology market
21
Marketing and Growth Strategy
Petlifes primary marketing strategy is premised
on building brand awareness, and rapid
penetration of strategic geographical markets.
Infomercials Both online and offline to educate
pet owners about cancer risk in Pets.
Product bundling - market Escozine for Pets
and supplements as treatments that
symbiotically work with one another and can
effectively treat cancer in pets.
Multi-local launches-Running online and offline
launches for each new geographical market. This
will help localize and establish PetLifes brand
and products, and help improve Google search
rankings
22
Partnership is our winning strategy
PetLife will sell Escozine for PetsTM to
veterinarians using multiple respected
veterinarian centers of influence to promote the
product. Incentives will be provided to
veterinarians to market the companys products.
Independent veterinarians will voluntarily help
the company conduct clinical trials of its drugs.
23
Financial Projections
Escozine for Pets line of nutraceuticals will
launch in 2017, helping the business immediately
start generating cash.
High product margins and slow increase in
operating costs against sales.
High product margins, and fast revenue growth
across all product categories (more than 100
sales growth in the first three years) will see
the company in a healthy cash positition
24
Investment Proposal
Petlife Pharma is seeking to raise 8.5 million
through a private placement offering to fund the
approval and launch of Escozine for Pets. The
initial part of our raise is 400,000.
  • 6.88 million is earmarked for Multi-Center
    Clinical Studies for Escozine for Pets. These
    studies will include testing of safety and
    toxicity as well as determining appropriate doing
    parameters. It is estimated that these studies
    can be completed in 18-22 months
  • Once initial safety and toxicity studies are
    performed the Company may consider applying for
    Compassionate Use approval in certain animal
    cancers. This could occur in a few as 9 months.

25
Investment Proposal
In return for 8.5 million, the company shall
issue 17,000,000 shares to investors, which are
equal to a 22.5 stake in the company after
dilution.
Shareholder Common Shares CommonOptions Phase One Invested Phase OneShares Phase One Fully DilutedShares FullyDiluted
Irrevocable de Fidecomison Confianza General De Familiar Irrevocable 30,700,000 - 0 - 0.0 30,700,000 40.6
Grand Street Ventures 5,700,000 - 0 - 0.0 5,700,000 7.5
Shareholders with under 5 11,083,652 - 0 - 0.0 11,083,652 14.6
Elite International Partners, Inc. 11,203,125 - 0 - 0.0 11,203,125 14.8
Phase One Investors 1 - - 8,500,000 17,000,000 100.0 17,000,000 22.5
Total 58,686,777 - 8,500,000 17,000,000 100.0 75,686,777 100.0
26
Investment Proposal
High Free Cash Flow generating potential
27
Key Milestones
28
Sources
  • DRESSLER, D. (2009). Palladia, First Dog Cancer
    Drug FDA Approved But Not Great. Retrieved May
    29, 2016, from
  • http//www.dogcancerblog.com/blog/first-dog-c
    ancer-drug-fda-approved-but-not-great/
  • The Ins and Outs of Cancer in Pets. (2016).
    Retrieved May 29, 2016, from
  • http//www.vosrc.net/blog/the-ins-and-outs-of
    -cancer-in-pets/
  • How Much Does Dog Cancer Treatment Cost? -
    CostHelper.com. (n.d.). Retrieved May 29, 2016,
    from
  • http//pets.costhelper.com/dog-cancer-treatme
    nt.html
  • Multi-center, placebo-controlled, double-blind,
    randomized study of oral toceranib phosphate
    (SU11654), a receptor tyrosine kinase inhibitor,
    for the treatment of dogs with recurrent (either
    local or distant) mast cell tumor following
    surgical excision. (2009, June/July). Retrieved
    May 29, 2016, from
  • http//www.ncbi.nlm.nih.gov/pubmed/19470739
  • Pet Cancer Facts and Figures. (n.d.). Retrieved
    May 29, 2016, from
  • http//www.petinsurance.com/healthzone/pet-ar
    ticles/pet-infographics/Pet-Cancer-Facts-and-Figur
    es-Infographic.aspx
  • Pet Industry Market Size Ownership Statistics.
    (n.d.). Retrieved May 29, 2016, from
  • http//www.americanpetproducts.org/press_indu
    strytrends.asp
  • Rusk, A., Dr. (n.d.). Cancer is the leading cause
    of death in dogs and cats. Retrieved May 29,
    2016, from
About PowerShow.com